Top Section/Ad
Top Section/Ad
Most recent
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
◆ Single digit premiums offered ◆ Reverse Yankees dominating euro supply ◆ Floaters proving popular with multi-tranche issuers
Pair enjoyed strong execution and tight pricing as US high grade credit remained resilient in the face of a sell-off in equity markets
More articles/Ad
More articles/Ad
More articles
-
The final size of the base deal will be Sfr2bn after the IPO was priced at the top of the range -
The biggest IPO of the year so far in Europe is multiple times covered, according to sources
-
KBRA expects to upgrade deal if merger with Orangetheory goes through
-
US drug maker's stake in Haleon set to fall to 24%
-
Risk appetite is back and more deals coming, though one bad IPO would damage confidence in the recovery
-
More companies are getting ratings to woo bond investors
